Bisphosphonates (e.g., alendronate, etidronate, ibandronate, risedronate, risedronate delayed release, tiludronate), were evaluated on September 9, 2011 at a Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory meeting.
Bisphosphonate studies have shown that these agents have proven beneficial within the first three years of treatment in preventing osteoporosis fractures. However, when treatment is continued beyond five years, there does not appear to be a use benefit compared with using “no drug.”
